Table 1: T2D Pathophysiology
Table 2: Symptoms of T2D
Table 3: Risk Factors and Comorbidities for T2D
Table 4: 9MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of T2D
Table 5: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CKD Among Diagnosed Prevalent Cases of T2D
Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of CVD Among Diagnosed Prevalent Cases of T2D
Table 7: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Overweight and Obesity Among Diagnosed Prevalent Cases of T2D
Table 8: 9MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Hypertension Among Diagnosed Prevalent Cases of T2D
Table 9: 8MM, Sources of Epidemiological Data Used to Forecast the Prevalent Cases of Dyslipidemia Among Diagnosed Prevalent Cases of T2D
Table 10: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, Ages =20 Years, N, 2015–2025
Table 11: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N (Row %), 2015
Table 12: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, Ages =20 Years, N (Row %), 2015
Table 13: Diagnostic Tests and Typical Criteria for T2D
Table 14: T2D Treatments
Table 15: Country Profile, T2D Management – US
Table 16: Country Profile, T2D Management – France
Table 17: Country Profile, T2D Management – Germany
Table 18: Country Profile, T2D Management – Italy
Table 19: Country Profile, T2D Management – Spain
Table 20: Country Profile, T2D Management – UK
Table 21: Country Profile, T2D Management – Japan
Table 22: Country Profile, T2D Management – China
Table 23: Country Profile, T2D Management – India
Table 24: Leading Branded Treatments for T2D, 2015
Table 25: Product Profile – Metformin
Table 26: Metformin SWOT Analysis, 2015
Table 27: Global Sales Forecasts ($M) for Metformin, 2015–2025
Table 28: First-Generation SUs
Table 29: Second-Generation SUs
Table 30: Product Profile – SUs
Table 31: SUs SWOT Analysis, 2015
Table 32: Global Sales Forecasts ($M) for SUs and non-SUs, 2015–2025
Table 33: Product Profile – Acarbose
Table 34: AGIs SWOT Analysis, 2015
Table 35: Global Sales Forecasts ($M) for AGIs, 2015–2025
Table 36: Product Profile – Actos
Table 37: TZDs SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($M) for TZDs, 2015–2025
Table 39: GLP-1RAs
Table 40: Product Profile – Byetta
Table 41: Byetta SWOT Analysis, 2015
Table 42: Global Sales Forecasts ($M) for Byetta, 2015–2025
Table 43: Product Profile – Victoza
Table 44: Victoza SWOT Analysis, 2015
Table 45: Global Sales Forecasts ($M) for Victoza, 2015–2025
Table 46: Product Profile – Bydureon
Table 47: Bydureon SWOT Analysis, 2015
Table 48: Global Sales Forecasts ($M) for Bydureon, 2015–2025
Table 49: Product Profile – Lyxumia
Table 50: Lyxumia SWOT Analysis, 2015
Table 51: Global Sales Forecasts ($M) for Lyxumia, 2015–2025
Table 52: Product Profile – Tanzeum
Table 53: Tanzeum SWOT Analysis, 2015
Table 54: Global Sales Forecasts ($M) for Tanzeum, 2015–2025
Table 55: Product Profile – Trulicity
Table 56: Trulicity SWOT Analysis, 2015
Table 57: Global Sales Forecasts ($M) for Trulicity, 2015–2025
Table 58: Marketed DPP-4Is
Table 59: Marketed DPP-4Is in Combination with Other OADs
Table 60: Product Profile – Januvia
Table 61: Januvia SWOT Analysis, 2015
Table 62: Global Sales Forecasts ($M) for Januvia, Janumet, Janumet XR, 2015–2025
Table 63: Product Profile – Onglyza
Table 64: Onglyza SWOT Analysis, 2015
Table 65: Global Sales Forecasts ($M) for Onglyza, Kombiglyze, XR, 2015–2025
Table 66: Product Profile – Tradjenta
Table 67: Tradjenta SWOT Analysis, 2015
Table 68: Global Sales Forecasts ($M) for Tradjenta, Jentadueto, 2015–2025
Table 69: Product Profile – Galvus
Table 70: Galvus SWOT Analysis, 2015
Table 71: Global Sales Forecasts ($M) for Galvus, Eucreas, 2015–2025
Table 72: Product Profile – Nesina
Table 73: Nesina SWOT Analysis, 2015
Table 74: Global Sales Forecasts ($M) for Nesina, Oseni, Kazano, 2015–2025
Table 75: Product Profile – Tenelia
Table 76: Tenelia SWOT Analysis, 2015
Table 77: Global Sales Forecasts ($M) for Tenelia, 2015–2025
Table 78: Product Profile – Suiny
Table 79: Suiny SWOT Analysis, 2015
Table 80: Global Sales Forecasts ($M) for Suiny, 2015–2025
Table 81: Product Profile – Zafatek
Table 82: Zafatek SWOT Analysis, 2015
Table 83: Global Sales Forecasts ($M) for Zafatek, 2015–2025
Table 84: SGLT-2Is
Table 85: Marketed SGLT-2Is in Combination with Other T2D Drugs
Table 86: Product Profile – Forxiga
Table 87: Forxiga SWOT Analysis, 2015
Table 88: Global Sales Forecasts ($M) for Forxiga, Xigduo XR, SaxaDapa, SaxaDapa + metformin, 2015–2025
Table 89: Product Profile – Invokana
Table 90: Invokana SWOT Analysis, 2015
Table 91: Global Sales Forecasts ($M) for Invokana, InvokaMet, XR, IR, 2015–2025
Table 92: Product Profile – Jardiance
Table 93: Jardiance SWOT Analysis, 2015
Table 94: Global Sales Forecasts ($M) for Jardiance, Synjardy, Glyxambi, 2015–2025
Table 95: Product Profile – Apleway
Table 96: Apleway SWOT Analysis, 2015
Table 97: Global Sales Forecasts ($M) for Apleway, 2015–2025
Table 98: Product Profile – Suglat
Table 99: Suglat SWOT Analysis, 2015
Table 100: Global Sales Forecasts ($M) for Suglat, 2015–2025
Table 101: Product Profile – Lusefi
Table 102: Lusefi SWOT Analysis, 2015
Table 103: Global Sales Forecasts ($m) for Lusefi, 2015–2025
Table 104: Insulins – Overview and Comparison
Table 105: Insulin Formulations
Table 106: Product Profile – Humalog
Table 107: Humalog SWOT Analysis, 2015
Table 108: Global Sales Forecasts ($M) for Humalog, Humalog Mixes, Humalog 200U, 2015–2025
Table 109: Product Profile – Lantus
Table 110: Lantus SWOT Analysis, 2015
Table 111: Global Sales Forecasts ($M) for Lantus, Toujeo LixiLan, 2015–2025
Table 112: Toujeo SWOT Analysis, 2015
Table 113: Product Profile – Levemir
Table 114: Levemir SWOT Analysis, 2015
Table 115: Global Sales Forecasts ($M) for Levemir, 2015–2025
Table 116: Product Profile – NovoLog
Table 117: NovoLog SWOT Analysis, 2015
Table 118: Global Sales Forecasts ($M) for NovoRapid, NovoMix, FIAsp, 2015–2025
Table 119: Product Profile – Apidra
Table 120: Apidra SWOT Analysis, 2015
Table 121: Global Sales Forecasts ($M) for Apidra, 2015–2025
Table 122: Product Profile – Tresiba
Table 123: Tresiba SWOT Analysis, 2015
Table 124: Global Sales Forecasts ($M) for Tresiba, Xultophy, Ryzodeg, 2015–2025
Table 125: Product Profile – Afrezza
Table 126: Afrezza SWOT Analysis, 2015
Table 127: Global Sales Forecasts ($M) for Afrezza, 2015–2025
Table 128: Unmet Needs and Opportunities in T2D
Table 129: T2D – Clinical Trials by Phase and Status, 2015
Table 130: T2D – Phase Pipeline, 2015
Table 131: Comparison of Therapeutic Classes in Development for T2D, 2015
Table 132: Product Profile – Semaglutide
Table 133: Semaglutide SWOT Analysis, 2015
Table 134: Global Sales Forecasts ($M) for Semaglutide, 2015–2025
Table 135: Product Profile – OG217SC
Table 136: OG217SC SWOT Analysis, 2015
Table 137: Global Sales Forecasts ($M) for OG217SC, 2015–2025
Table 138: Product Profile – ITCA 650
Table 139: ITCA-650 SWOT Analysis, 2015
Table 140: Global Sales Forecasts ($M) for ITCA-650, 2015–2025
Table 141: Product Profile – Marizev
Table 142: Marizev SWOT Analysis, 2015
Table 143: Global Sales Forecasts ($M) for Marizev, 2015–2025
Table 144: Product Profile – Ertugliflozin
Table 145: Ertugliflozin SWOT Analysis, 2015
Table 146: Global Sales Forecasts ($M) for Ertugliflozin, Ertugliflozin + metformin, Sitagliptin + Ertugliflozin, 2015–2025
Table 147: Product Profile – FIAsp
Table 148: FIAsp SWOT Analysis, 2015
Table 149: Product Profile – Abasaglar
Table 150: Abasaglar SWOT Analysis, 2015
Table 151: Global Sales Forecasts ($M) for Abasaglar, 2015–2025
Table 152: Key Companies in the T2D Market, 2015
Table 153: Other Companies in the T2D Market, 2015
Table 154: Eli Lilly’s T2D Portfolio Assessment, 2015
Table 155: Eli Lilly SWOT Analysis, 2015
Table 156: Novo Nordisk’s T2D Portfolio Assessment, 2015
Table 157: Novo Nordisk SWOT Analysis, 2015
Table 158: Sanofi’s T2D Portfolio Assessment, 2015
Table 159: Sanofi SWOT Analysis, 2015
Table 160: GSK’s T2D Portfolio Assessment, 2015
Table 161: GSK SWOT Analysis, 2015
Table 162: AstraZeneca’s T2D Portfolio Assessment, 2015
Table 163: AstraZeneca SWOT Analysis, 2015
Table 164: Merck’s T2D Portfolio Assessment, 2015
Table 165: Merck SWOT Analysis, 2015
Table 166: BI’s T2D Portfolio Assessment, 2015
Table 167: BI SWOT Analysis, 2015
Table 168: Takeda’s T2D Portfolio Assessment, 2015
Table 169: Takeda SWOT Analysis, 2015
Table 170: Roche’s T2D Portfolio Assessment, 2015
Table 171: Roche SWOT Analysis, 2015
Table 172: Pfizer’s T2D Portfolio Assessment, 2015
Table 173: Pfizer SWOT Analysis, 2015
Table 174: J&J’s T2D Portfolio Assessment, 2015
Table 175: J&J SWOT Analysis, 2015
Table 176: Novartis’ T2D Portfolio Assessment, 2015
Table 177: Novartis SWOT Analysis, 2015
Table 178: Intarcia Therapeutics’ T2D Portfolio Assessment, 2015
Table 179: Intarcia Therapeutics SWOT Analysis, 2015
Table 180: Global Sales Forecasts ($M) for T2D, 2015–2025
Table 181: T2D Market – Drivers and Barriers, 2015
Table 182: Sales Forecasts ($M) for T2D in the US, 2015–2025
Table 183: Key Events Impacting Sales for T2D in the US, 2015–2025
Table 184: T2D Market – Drivers and Barriers in the US, 2015
Table 185: Sales Forecasts ($M) for T2D in France, 2015–2025
Table 186: Key Events Impacting Sales for T2D in France, 2015–2025
Table 187: T2D Market – Drivers and Barriers in France, 2015
Table 188: Sales Forecasts ($M) for T2D in Germany, 2015–2025
Table 189: Key Events Impacting Sales for T2D in Germany, 2015–2025
Table 190: T2D Market – Drivers and Barriers in Germany, 2015
Table 191: Sales Forecasts ($M) for T2D in Italy, 2015–2025
Table 192: Key Events Impacting Sales for T2D in Italy, 2015–2025
Table 193: T2D Market – Drivers and Barriers in Italy, 2015
Table 194: Sales Forecasts ($M) for T2D in Spain, 2015–2025
Table 195: Key Events Impacting Sales for T2D in Spain, 2015–2025
Table 196: T2D Market – Drivers and Barriers in Spain, 2015
Table 197: Sales Forecasts ($M) for T2D in the UK, 2015–2025
Table 198: Key Events Impacting Sales for T2D in the UK, 2015–2025
Table 199: T2D Market – Drivers and Barriers in the UK, 2015
Table 200: Sales Forecasts ($M) for T2D in Japan, 2015–2025
Table 201: Key Events Impacting Sales for T2D in Japan, 2015–2025
Table 202: T2D Market – Drivers and Barriers in Japan, 2015
Table 203: Sales Forecasts ($M) for T2D in China, 2015–2025
Table 204: Key Events Impacting Sales for T2D in China, 2015–2025
Table 205: T2D Market – Drivers and Barriers in China, 2015
Table 206: Sales Forecasts ($M) for T2D in India, 2015–2025
Table 207: Key Events Impacting Sales for T2D in India, 2015–2025
Table 208: T2D Market – Drivers and Barriers in India, 2015
Table 209: Key Launch Dates
Table 210: Key Patent Expiries
Table 211: Number of High-Prescribing Physicians Surveyed